Abstract 1996P
Background
Avelumab maintenance therapy is the standard of care for advanced UC (aUC) that has not progressed after prior chemotherapy based on the JAVELIN Bladder 100 phase 3 (JB100) trial. We report primary analyses of PMS data for the safety and effectiveness of avelumab maintenance in pts with aUC in clinical practice in Japan.
Methods
This PMS is a multicenter, observational surveillance of pts with aUC without disease progression after prior chemotherapy who received ≥1 dose of avelumab from Feb 24, 2021, to Dec 7, 2021. Data on safety and effectiveness were collected from the start of avelumab therapy for ≤52 weeks and analyzed by descriptive statistics and Kaplan-Meier methods.
Results
This analysis included 453 pts. Median age was 73.0 years (Q1-Q3, 68.0-78.0), including 180 pts (39.7%) older than 75 years. Primary tumor site was bladder in 244 pts (53.9%) and upper tract in 209 (46.1%). ECOG performance status was 0-1 in 436 pts (96.2%). Prior chemotherapy was gemcitabine + cisplatin in 267 pts (58.9%) and gemcitabine + carboplatin in 163 (36.0%). Response to chemotherapy was complete response in 47 pts (10.4%), partial response in 242 (53.4%), and stable disease in 149 (32.9%). Median observation period was 52.0 weeks (range, 3.6-52.0); at data cutoff (Mar 6, 2024), 128 pts (28.3%) remained on avelumab treatment and 184 pts (40.6%) received subsequent next-line treatment. Adverse drug reactions (ADRs) of safety specifications (SS; any grade) with avelumab occurred in 144 pts (31.8%), including grade ≥3 in 35 (7.7%); the most common any-grade ADRs of SS (≥5% of pts) were infusion reaction in 53 (11.7%) and thyroid dysfunction in 33 (7.3%). 32 pts (9.8%) had an ADR of SS that led to treatment discontinuation. Median overall survival (OS) was not reached and the 1-year OS rate was 77.9% (95% CI, 73.7-81.5).
Conclusions
The primary analysis of this PMS is the largest real-world data set of avelumab maintenance therapy in Asia, observing patients in clinical practice. The safety profile, tolerability, and effectiveness of avelumab maintenance therapy in this PMS were comparable to findings from JB100 and real-world studies from other countries.
Clinical trial identification
the University hospital medical information network clinical trials registry (UMIN-CTR: UMIN 43435).
Editorial acknowledgement
Editorial support was provided by Nucleus Global and was funded by Merck.
Legal entity responsible for the study
Merck Biopharma Co., Ltd., Tokyo, Japan, an affiliate of Merck KGaA.
Funding
This work was supported by Merck Biopharma Co., Ltd., Tokyo, Japan, an affiliate of Merck KGaA (CrossRef Funder ID: 10.13039/100009945) and was previously conducted under an alliance between Merck and Pfizer.
Disclosure
E. Kikuchi: Financial Interests, Personal, Advisory Role: Astellas Pharma, AstraZeneca, Bristol Myers Squibb-Ono Pharmaceutical, Chugai Pharmaceutical, Janssen, Merck, MSD, Pfizer; Financial Interests, Personal, Speaker’s Bureau: Astellas Pharma, AstraZeneca, Bayer, Bristol Myers Squibb-Ono Pharmaceutical, Chugai Pharmaceutical, Janssen, Kissei Pharmaceutical, Kyorin, Merck, MSD, Nippon Kayaku, Nippon Shinyaku, Pfizer, Sanofi, Taiho Pharmaceutical, Takeda, Kyowa Kirin International; Financial Interests, Institutional, Research Funding: Chugai Pharmaceutical, Kissei Pharmaceutical, Kyorin, Kyowa Kirin International, Nippon Kayaku, Nippon Shinyaku, Otsuka, Sanofi, Taiho Pharmaceutical, Takeda. T. Ito, M. Sato, M. Ogi, M. Morita, M. Kajita: Financial Interests, Personal, Full or part-time Employment: Merck Biopharma Co., Ltd., Tokyo, Japan, an affiliate of Merck KGaA. H. Nishiyama: Financial Interests, Personal, Speaker’s Bureau: Astellas Pharma, Merck, MSD, Olympus; Financial Interests, Personal, Research Funding: Chugai Pharmaceutical, Ono Pharmaceutical. All other authors have declared no conflicts of interest.
Resources from the same session
242P - Clinical outcomes in patients (pts) with HR+/HER2− early breast cancer (EBC) by prior systemic treatment (tx): A subgroup analysis of the NATALEE trial
Presenter: Nicholas McAndrew
Session: Poster session 13
243P - Prognosis of patients with hormone receptor-positive/HER2-negative early breast cancer according to monarchE and NATALEE trials risk categories: Patient-level analysis of Mammella InterGruppo (MIG) and Gruppo Italiano Mammella (GIM) randomised trials
Presenter: Luca Arecco
Session: Poster session 13
244P - Efficacy and safety of dalpiciclib, exemestane, and goserelin as neoadjuvant therapy in premenopausal HR-positive, HER2-negative breast cancer patients: A phase II clinical trial
Presenter: Yang Zhengjun
Session: Poster session 13
245P - Characteristics of real-world (RW) NATALEE and monarchE eligible populations: A US electronic health records (EHR) database analysis
Presenter: Paolo Tarantino
Session: Poster session 13
246P - Axillary management and outcomes after neoadjuvant endocrine therapy in the randomized PELOPS trial
Presenter: Anna C. Weiss
Session: Poster session 13
247P - Concurrent versus sequential adjuvant chemoradiotherapy in early-stage breast cancer: A systematic review and meta-analysis
Presenter: Luiz Felipe de Almeida
Session: Poster session 13
248P - Impact of unilateral mastectomy with or without immediate breast reconstruction on vertebral alignment
Presenter: Jong-Ho Cheun
Session: Poster session 13
249P - Neoadjuvant chemotherapy in inflammatory breast cancer: A meta-analysis of 10 trials of the German Breast Group (GBG)
Presenter: Laura Michel
Session: Poster session 13
250P - Development and validation of a 19-feature classifier that predicts response to neoadjuvant trastuzumab emtansine (T-DM1) in breast cancer patients
Presenter: Fresia Pareja
Session: Poster session 13